OptiMedica Corp., a Sunnyvale, California startup, has raised $35 million, according to a recent regulatory filing.
Earlier in November, the company announced that a portion of the money would be used to market its Catalys Precision System globally. Existing investors — Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital — poured more money into the company. The $35 million round comes three years after the company raised $30.5 million in 2009, per a previous regulatory submission.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
“OptiMedica has been committed to bringing the precision and safety benefits of femtosecond laser technology to cataract surgery since our founding in 2004. Today, we are literally standing at the forefront of a landscape shift in the field that, we believe, will ultimately make the laser the centerpiece of the procedure,” said Mark J. Forchette, OptiMedica president and CEO, in a news release.
One of the benefits of cataract surgery using lasers is that it reduces the need for ultrasound to remove the lens from a patient and the procedure is considered to be something that revolutionizes cataract surgery.
The U.S. Food and Drug Administration-cleared and CE-Marked Catalys Precision System has been used in more than 6,000 laser cataract surgeries in 10 countries.
“The rapid worldwide adoption of Catalys is not only a direct result of the system’s unparalleled performance but also of the amazing talent and unique Silicon Valley culture that you’ll find at OptiMedica,” said Brook Byers, partner, Kleiner Perkins Caufield & Byers, and chairman of the board, OptiMedica, noted in the release.
